FcRn Pathway Inhibition in ITP

Download this slideset on expert perspectives on FcRn pathway inhibition in patients with ITP.
David J. Kuter, MD, DPhil
Format: Microsoft PowerPoint (.ppt)
File Size: 2.35 MB
Released: July 23, 2021


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
UCB Biopharma SRL

Related Content

CCO Conference Coverage of ASH 2021 with downloadable slides and experts’ commentaries of clinically relevant studies

John M. Burke, MD Amy E. DeZern, MD, MHS Shaji K. Kumar, MD Sagar Lonial, MD Peter Martin, MD Mark A. Schroeder, MD Sujit Sheth, MD B Douglas Smith B. Douglas Smith, MD Srdan Verstovsek, MD, PhD Eunice S. Wang, MD Released: December 8, 2021

Commentary on considerations affecting therapy recommendations for patients with myeloma in the evolving treatment landscape, from Clinical Care Options (CCO)

Brian G.M. Durie, MD
Program Director
Thomas G. Martin, MD Philippe Moreau, MD S. Vincent Rajkumar, MD Jesús F. San-Miguel, MD, PhD
Released: December 7, 2021

Commentary from Dr. Julie Vose on how to select therapy for patients with EBV-positive PTLD, from Clinical Care Options (CCO)

Julie M. Vose, MD, MBA Released: December 6, 2021

Interactive online tool with expert recommendations for assessing and managing adverse events associated with BTK inhibitors, from Clinical Care Options

Farrukh T. Awan, MD Christopher R. Flowers, MD, MS Nicole Lamanna, MD John P. Leonard, MD Julie M. Vose, MD, MBA Released: December 6, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.